The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: A promising candidate for epidermal growth factor receptor-targeted therapy?

Kalliopi P. Siziopikou*, Reshma Ariga, Kimon E. Proussaloglou, Paolo Gattuso, Melody Cobleigh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

While epidermal growth factor receptor (EGFR)-targeted therapy has been very promising in a number of human malignancies, to date these targeted biologic agents have not proven effective in breast cancer. However, the EGFR tyrosinase inhibitors have been used indiscriminately against all types of breast tumors, perhaps missing a subpopulation of patients who may be prime candidates for EGFR-targeted therapy. In this communication we propose that patients with estrogen receptor (ER)-negative/progesterone receptor (PR)-negative/HER-2-negative tumors, which currently present a therapeutic challenge for the oncologist, may be the subgroup of breast cancer patients that might benefit from specific EGFR-targeted therapies.

Original languageEnglish (US)
Pages (from-to)360-362
Number of pages3
JournalBreast Journal
Volume12
Issue number4
DOIs
StatePublished - Jul 2006

Keywords

  • Breast cancer
  • EGFR
  • HER-2
  • Targeted therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2-negative patient: A promising candidate for epidermal growth factor receptor-targeted therapy?'. Together they form a unique fingerprint.

Cite this